Report a side effect Contact Us
  • Who We Are
    Who We Are
    EIPICO was established in Tenth of Ramadan City in 1980, with a capital of EGP 7 Million.
    • Overview
    • Vision, Mission & Values
    • Our History
    • Chairman Message
    • News and Media
      • Press Releases
      • Media Library
    • Sustainability & CSR
  • Manufacturing Facilities
    Manufacturing Facilities
    EIPICO is the Leading Egyptian Pharmaceutical Company, in Production, by Units. It is the Major Provider of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.


    • Overview
    • Factory 1
    • Factory 2
    • Factory 3
    • Eiaco Factory
    • Eipico Plastic Factory
    • Industry Expansion
  • Science & Medicine
    Science & Medicine
    EIPICO provides High Quality Pharmaceutical Products at reasonable prices, thus assisting human healthcare improvement .
    • Products
    • Products (Alphabetical)
    • R&D and Quality
    • Global Accreditation
    • Regulatory Affairs
  • Global
    Global
    EIPICO is ranked Number 1 in Egyptian Exports of Pharmaceutical Products, capturing 29% of Egypt’s Total Exports of Pharmaceutical Products, by Value.
    • Overview
    • Our Export History
    • Eipico Destination
  • Investor Relations
    Investor Relations
    • Investor Relations
    • Annual Reports
  • EIPICO 3
    EIPICO 3
    The First Modular Biological and Biosimilar Facility in Egypt
    • EIPICO 3 (Biologicals & Biosimilars)
Epicopred


Display

Display

  • Therapeutic indications
  • Therapeutic Indication :

    Collagenosis-connectivitis:

      Progressive attacks of systemic diseases, in particular: systemic lupus erythematosus,    vasculitis, polymyositis, visceral sarcoidosis.

    Dermatological: Severe autoimmune bullous dermatoses, in particular pemphigus and    bullous pemphigoid.

    Digestive: Progressive outbreaks of ulcerative colitis and Crohn's disease.

    Nephrological: Nephrotic syndrome with minimal glomerular lesions.

    Neurological: Myasthenia gravis. Cerebral edema of tumor cause. Multiple sclerosis in flare, after intravenous corticosteroid therapy.

    Respiratory: Persistent asthma preferably in short course in the event of failure of inhaled treatment at high doses.

    Rheumatological: Rheumatoid arthritis and certain polyarthritis.

    Transplantation of organ and allogenic hematopoietic stem cells: Prophylaxis or treatment of transplant rejection






WE ARE EIPICO

EIPICO was established in Tenth of Ramadan City in 1980, with a capital of EGP 7 Million, currently raised to EGP 1500 Million.

Quick Links

  • EIPICO 3
  • News
  • Products
  • Global accreditation
  • Global
  • Investor relations

Contact Us

EIPICO, Tenth of Ramadan City - 1st Industrial Zone B1, Egypt.

Telephone : +20554499199
Fax : +20554499306

eipico@eipico.com.eg

Back to top
Powered by EIPICO Team
     Visitors Count : 1870040